Mylan N.V. is a global pharmaceutical company with a well-established generics business as well as a presence in specialty pharmaceuticals. The company’s business model includes the development, manufacturing and marketing of branded and generic drugs as well as active pharmaceutical ingredients (APIs) in North America, Europe and Rest of World. Notably, Mylan has one of the world’s largest API operations.
Mylan has one of the largest product portfolios among all generic pharmaceutical companies. After a challenging 2017, things are looking up for Mylan in 2018. The company got a major boost with the FDA’s approval of a generic version of Copaxone 40 mg. Although volatility in the U.S. market is expected to persist in 2018, yet these approvals should position Mylan better in the year ahead and help combat the decline in EpiPen sales. The company has more than 30 submissions planned in 2018.
The company’s performance has been mixed so far, having topped earnings estimates in two and missing in other two of the trailing four quarters. The company reported an average negative earnings surprise of 3.53% over the said time frame.
Currently, Mylan has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Mylan missed on earnings. Our consensus called for EPS of $0.99, and the company reported EPS of $0.96.
Revenue: Revenues too missed expectations. Mylan posted revenues of $2.7 billion, compared to our consensus estimate of $2.78 billion.
Key Stats: Challenges in North America continue to impact performance primarily due to the combined impact of the loss of exclusivity on the olmesartan products, lower sales of branded products, including the EpiPen Auto-Injector, the divestiture of certain contract manufacturing assets and the impact of the adoption of new accounting standards.
Pre-Market Trading: Shares are trading down in pre-market trading.
Check back later for our full write up on this Mylan earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Image: Bigstock
Mylan Misses on Earnings and Sales in Q1
Mylan N.V. is a global pharmaceutical company with a well-established generics business as well as a presence in specialty pharmaceuticals. The company’s business model includes the development, manufacturing and marketing of branded and generic drugs as well as active pharmaceutical ingredients (APIs) in North America, Europe and Rest of World. Notably, Mylan has one of the world’s largest API operations.
Mylan has one of the largest product portfolios among all generic pharmaceutical companies. After a challenging 2017, things are looking up for Mylan in 2018. The company got a major boost with the FDA’s approval of a generic version of Copaxone 40 mg. Although volatility in the U.S. market is expected to persist in 2018, yet these approvals should position Mylan better in the year ahead and help combat the decline in EpiPen sales. The company has more than 30 submissions planned in 2018.
The company’s performance has been mixed so far, having topped earnings estimates in two and missing in other two of the trailing four quarters. The company reported an average negative earnings surprise of 3.53% over the said time frame.
Currently, Mylan has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Mylan missed on earnings. Our consensus called for EPS of $0.99, and the company reported EPS of $0.96.
Revenue: Revenues too missed expectations. Mylan posted revenues of $2.7 billion, compared to our consensus estimate of $2.78 billion.
Mylan N.V. Price, Consensus and EPS Surprise
Mylan N.V. Price, Consensus and EPS Surprise | Mylan N.V. Quote
Key Stats: Challenges in North America continue to impact performance primarily due to the combined impact of the loss of exclusivity on the olmesartan products, lower sales of branded products, including the EpiPen Auto-Injector, the divestiture of certain contract manufacturing assets and the impact of the adoption of new accounting standards.
Pre-Market Trading: Shares are trading down in pre-market trading.
Check back later for our full write up on this Mylan earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>